Tabula Rasa HealthCare Inc. (NASDAQ:TRHC) went up by 0.57% from its latest closing price compared to the recent 1-year high of $69.31. The company’s stock price has collected -5.33% of loss in the last five trading sessions. Press Release reported on 11/15/21 that Tabula Rasa HealthCare Announces Five-Year Contract Extension with Rocky Mountain PACE
Is It Worth Investing in Tabula Rasa HealthCare Inc. (NASDAQ :TRHC) Right Now?
Plus, the 36-month beta value for TRHC is at 0.83. Opinions of the stock are interesting as 3 analysts out of 7 who provided ratings for Tabula Rasa HealthCare Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $22.83, which is $11.9 above the current price. TRHC currently public float of 21.23M and currently shorts hold a 9.32% ratio of that float. Today, the average trading volume of TRHC was 451.81K shares.
TRHC’s Market Performance
TRHC stocks went down by -5.33% for the week, with a monthly drop of -54.95% and a quarterly performance of -60.24%, while its annual performance rate touched -66.54%. The volatility ratio for the week stands at 9.54% while the volatility levels for the past 30 days are set at 12.49% for Tabula Rasa HealthCare Inc.. The simple moving average for the period of the last 20 days is -32.70% for TRHC stocks with a simple moving average of -67.11% for the last 200 days.
Analysts’ Opinion of TRHC
Many brokerage firms have already submitted their reports for TRHC stocks, with Robert W. Baird repeating the rating for TRHC by listing it as a “Outperform.” The predicted price for TRHC in the upcoming period, according to Robert W. Baird is $53 based on the research report published on May 28th of the current year 2021.
Truist, on the other hand, stated in their research note that they expect to see TRHC reach a price target of $42, previously predicting the price at $41. The rating they have provided for TRHC stocks is “Hold” according to the report published on March 01st, 2021.
Piper Sandler gave a rating of “Neutral” to TRHC, setting the target price at $41 in the report published on February 25th of the current year.
TRHC Trading at -47.40% from the 50-Day Moving Average
After a stumble in the market that brought TRHC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.07% of loss for the given period.
Volatility was left at 12.49%, however, over the last 30 days, the volatility rate increased by 9.54%, as shares sank -52.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -56.92% lower at present.
During the last 5 trading sessions, TRHC fell by -5.33%, which changed the moving average for the period of 200-days by -77.70% in comparison to the 20-day moving average, which settled at $17.78. In addition, Tabula Rasa HealthCare Inc. saw -70.99% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at TRHC starting from Knowlton Orsula V, who sale 46,672 shares at the price of $12.95 back on Nov 17. After this action, Knowlton Orsula V now owns 386,057 shares of Tabula Rasa HealthCare Inc., valued at $604,402 using the latest closing price.
Knowlton Orsula V, the President of Tabula Rasa HealthCare Inc., sale 40,828 shares at $12.95 during a trade that took place back on Nov 17, which means that Knowlton Orsula V is holding 307,156 shares at $528,723 based on the most recent closing price.
Stock Fundamentals for TRHC
Current profitability levels for the company are sitting at:
- -18.87 for the present operating margin
- +15.94 for the gross margin
The net margin for Tabula Rasa HealthCare Inc. stands at -27.24. The total capital return value is set at -12.51, while invested capital returns managed to touch -18.59. Equity return is now at value -89.40, with -17.50 for asset returns.
Based on Tabula Rasa HealthCare Inc. (TRHC), the company’s capital structure generated 172.51 points at debt to equity in total, while total debt to capital is 63.30. Total debt to assets is 56.51, with long-term debt to equity ratio resting at 160.01. Finally, the long-term debt to capital ratio is 58.72.
When we switch over and look at the enterprise to sales, we see a ratio of 1.80, with the company’s debt to enterprise value settled at 0.24. The receivables turnover for the company is 7.88 and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.29.